IL6 and metabolic dysfunction-associated steatohepatitis: Clinical studies examining patients with hepatic steatosis or NASH found supplementation, twice daily, with L-TRP for 14 months result in decreased plasma LDL, TG, and gamma gluthamylo transpeptidase levels with a correlative decrease in plasma IL-1β, IL-6, and TNF (130, 131).